Testing the drug 2-HOBA in people with early Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new oral drug called 2-HOBA (a natural compound found in curry) in people with early-stage Alzheimer's. The drug may help protect brain cells and possibly slow memory decline. Participants will take the drug daily for a period, and researchers will monitor changes in cognition and biomarkers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 85 years old.
- You have either mild cognitive impairment or mild Alzheimer's disease (confirmed by a doctor).
- You have a study partner who can come with you to visits and answer questions.
- You are in overall good health, with no unstable major medical conditions.
- You are not taking any prohibited medications, and your memory medications (if any) have been stable for at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This trial tests an experimental drug called sodium pentaborate pentahydrate (a boron-based compound) in people with mild to moderate Alzheimer's. Researchers want to see if it's safe and if it can help slow memory and thinking problems.
This trial tests a new combination treatment (DAOIB and an antioxidant) for people with early Alzheimer's or mild cognitive impairment. It aims to see if the treatment can help slow or improve memory and thinking problems.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.